USE of probiotics for the management of acute gastroenteritis in chilldren : a systematic review
Abstract
One of the illnesses that affect children the most frequently is acute gastroenteritis. There are around 500 million children throughout the world who are affected by this illness each year. The acute infectious diarrhea that occurs in affluent nations often has a moderate clinical course, and symptoms typically disappear on their own within a few days. The assessment of dehydration is the most essential part of both diagnostic and therapeutic care since it establishes the degree of AGE and is one of the criteria that is considered when deciding whether or not a patient should be admitted to the hospital. Outpatient care is appropriate for the vast majority of patients; hospitalization should only be considered for individuals who require rehydration by enteral or parenteral routes. Oral rehydration with fluids of a hypoosmolar concentration is the initial therapy of choice. Antidiarrheals such as racecadotril and diosmectite, probiotics such as Lactobacillus GG and Saccharomyces boulardii, and ondansetron, which lessens the severity of nausea and vomiting, are also beneficial. Antibiotherapy is something that should only be explored in the most dire of circumstances. Acute diarrhea is a well-known medical condition that is straightforward to cure if the patient adheres to a few basic guidelines that have been clearly outlined. There is an insufficient amount of data to support the use of probiotics in either a therapeutic or preventative capacity for the treatment of acute…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 500 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.